Oral, esophageal cancers a higher risk in post-allogeneic hematopoietic stem cell transplantation patients: study

February 19, 2014

(BioNews) – New research has recently revealed there could be higher risk associated with the development of secondary solid cancers, oral cancers and esophageal cancers after receiving a treatment called allogeneic hematopoietic stem cell transplantation (allogeneic HSCT). HSCT, which involves the transplantation of multi potent hematopoietic stem cells into recipients that are extracted from bone marrow, peripheral blood, or umbilical cord blood, is regarded as a dangerous and complicated treatment that is typically reserved for blood or bone cancer patients whose immune systems have been virtually eviscerated from cancer treatments like radiation and chemotherapy.